白花蛇舌草抑制肝癌H22小鼠淋巴管转移的实验研究

目的:观察白花蛇舌草对小鼠肝癌淋巴管转移的影响。方法:在小鼠右下肢爪垫内侧皮下注射接种腹水型肝癌H22瘤株,复制淋巴管转移模型。将模型小鼠随机分为5组,空白组每天灌生理盐水,大、中、小剂量组每天灌白花蛇舌草水煎液,对照组给予环磷酰胺腹腔注射。观察小鼠体质量、免疫器官、肺部转移率、爪垫移植瘤、淋巴结转移瘤等指标变化。结果:白花蛇舌草作用组的小鼠,体质量和免疫器官胸腺质量明显增长,肺部瘤结节数和肺部转移瘤生长指数均下降,且淋巴结转移数明显减少。结论:白花蛇舌草对H22肝癌淋巴管转移有一定抑制作用。

HSPgp96与rIL-2治疗小鼠H22肝癌移植瘤的实验研究

目的 :研究热休克蛋白 gp96 (Heat- Shock Protein gp96 ,HSPgp96 ) -肽复合物瘤苗与重组人白介素 -2 (Recombinant Human Interleukin- 2 ,r IL- 2 )对小鼠 H2 2肝癌移植瘤的治疗效果。方法 :从 H2 2肝癌细胞中提取和纯化 HSPgp96。建立小鼠 H2 2肝癌移植瘤模型 ,应用 HSPgp96与 r IL - 2治疗并比较疗效 ,观察指标 :瘤重 ,光镜、电镜下观察组织结构。结果 :经鉴定获得纯化的 HSPgp96。HSPgp96 5 μg与 r IL- 2 2 5 ku治疗小鼠 H2 2肝癌有效。结论 :该实验方法提纯的 HSPgp96与重组人 IL - 2都能有效抑制小鼠 H2

Antitumor and synergistic effect of Chinese medicine “Bushen huayu jiedu recipe” and chemotherapy on transplanted animal hepatocarcinoma

AIM: To investigate the antitumor and synergistic effect of Chinese medicine 'Bushen huayu jiedu recipe' (recipe for invigorating the kidney, removing blood stasis and toxic substances) and chemotherapy on mice hepatocarcinoma.METHODS: Bushen huayu jiedu recipe (BSHYJDR)consisting of Chinese Cassia Bark, Psoralea, Zedoary,Rhubarb, etc. is equal to 1.5 g/mL liquid of originated herbs after being decocted, filtered, and concentrated. Kunming mice, weighing 18-22 g, were injected with 0.2 mL ascitic hepatocarcinoma H22 containing 1×107 cells/mL into armpit of the right forelimb of mice. After 24 h, the mice were weighed and randomly divided into tumor-bearing model control group, cisplatin (DDP) group, BSHYJDR high dosage group, low dosage BSHYJDR group, DDP combined with high and low dosage BSHYJDR group, 10 mice in each group. DDP group received injection intraperitoneally (ip) at the dosage of 1 mg/kg (equal to 1/10 LD50), once a day for 4 d. High and low dosage BSHYJDR groups received intragastric BSHYJDR at the dosages of 26.6 and 13.3 g/kg (20 and 10 times each of clinical adult dosage)respectively, while tumor-bearing model group received the equal volume of distilled water once a day for 10 d. On the 11th d, the mice were weighed and killed, then the tumor was dissected and weighed, the repression rate (RR) was calculated according to the mean weight of tumor (MWT).RESULTS: Compared to the model group (MWT: 1.30±0.73),DDP group (MWT: 0.41+0.09, RR: 68.46%) had a significant difference in the inhibition of hepatocarcinoma H22 (P＜0.01).High dosage BSHYJDR group (MWT: 0.69+0.29, RR:46.92%) also had a significant difference in inhibition (P＜0.05), while no difference was found in low dosage BSHYJDR group (MWT: 0.85+0.34, RR: 34.62%) (P＞0.05).When DDP was combined with high dosage BSHYJDR (MWT: 0.29±0.17, RR: 77.69%) and low dosage BSHYJDR (MWT: 0.38±0.21, RR: 70.77%) respectively, we could see improvement of the inhibition effect of DDP on transplanted hepatocarcinoma H22. DDP combined with high dosage BSHYJDR had a significant difference (P＜0.001) compared to DDP, while DDP combined with low dosage BSHYJDR only had a little improvement that is not remarkable.CONCLUSION: Chinese medicine BSHYJDR in combination with chemotherapy can inhibit transplanted hepatocarcinoma in mice.

Effect of dendritic cell modified by gp96-peptide complex on antitumor effect in H22 cell

Objective:To investigate the antitumor effect of dendritic cell （DC） modified by gp96-peptide complexes both in vitro and in vivo.Methods:Gp96-peptide complexes were acquired from H22 liver cancer cells in mice. DC were cultured from bone marrow cells and modified by gp96-peptide complexes. Spleen lymphocytes of mice were activated by modified DC and the cytotoxicity were detected by (（）51Cr) release method. Modified DC, gp96-peptide complexes and inactivated H22 cells were injected into mice bearing H22 liver cancer cells to observe the levels of IL-10, IFN-γ in serum and the alteration of proportions of CD8+-IFNγ+ and CD8+- IL-10+ cells, CD4+-IFNγ+ and CD4+- IL-10+ cells. Results:DC modified by gp96-peptide complexes can activate spleen lymphocyte and the latter can specifically kill H22 cells but not Ehrilich ascites carcinoma cells. Modified DC can improve the host’s antitumor immune response and the proportions of Th1 cells, inhibiting tumor growth. Conclusion: Gp96-peptide complexes can activate DC effectively, making DC a good vaccine.

扶正消瘤方对H_(22)荷瘤小鼠抑癌及其化疗减毒作用

目的考察扶正消瘤方(人参、黄芪、猪苓等)抗肝癌作用及其减轻环磷酰胺引起的毒性。方法 ICR小鼠采用右前肢皮下接种造H_(22)荷瘤模型,灌胃给予扶正消瘤方后,检测生命延长率、瘤重、抑瘤率、T淋巴细胞增殖率、血清超氧化物歧化酶(SOD)活性和丙二醛(MDA)水平。H_(22)荷瘤小鼠腹腔注射环磷酰胺(50 mg/kg),测定扶正消瘤方给药后血液学指标、血清溶血素水平及抗体形成细胞数。结果扶正消瘤方可明显抑制肿瘤生长,升高血清SOD活性,减少MDA水平,促进T淋巴细胞增殖。而且,它还能拮抗环磷酰胺引起的白细胞及血小板数量下降,并升高抗体形成细胞数。结论扶正消瘤方具有良好的抗肝癌作用,并能减轻化疗所致的毒性,可能与增强机体抗氧化和免疫能力有关。

青蒿琥酯对H_(22)小鼠肝癌的体内抑瘤作用

目的:探讨青蒿琥酯对H22小鼠肝癌的体内抑瘤作用。方法:取雌性KM小鼠40只,将H22小鼠肝癌细胞接种于小鼠右前肢腋皮下,随机分为模型对照组(Control)、环磷酰胺组(CTX)及青蒿琥酯(ASUN)30、90、150mg/kg低、中、高三个剂量组,共5组,每组8只。连续腹腔注射给药8天后,剥取瘤块和脾脏,称重,计算抑瘤率。结果:青蒿琥酯30、90、150mg/kg剂量组的抑瘤率分别为38.9%、31.1%和21.5%,抑瘤率随剂量增大而降低,其中青蒿琥酯30mg/kg剂量组与模型对照组比较,差异有统计学意义(P<0.05);荷瘤小鼠脾质量随青蒿琥酯剂量增加而增大。结论:青蒿琥酯对H22小鼠肝癌具有体内抑瘤作用。

羧甲基化裂褶多糖抗肝癌作用的实验研究

目的:从细胞水平和整体水平探讨羧甲基化裂褶多糖的抗肝癌作用。方法:将两种不同取代度羧甲基化裂褶多糖加入H22小鼠肝癌细胞液中分别培养24、48、72h,用台盼蓝拒染法测试作用后的细胞死亡率;建立小鼠H22肝癌移植性实体瘤模型,将其分为空白对照组、阳性对照组和3种不同取代度羧甲基化裂褶多糖给药组,腹腔注射给药,各组小鼠均连续给药10d后处死并称瘤重,计算抑瘤率。结果:不同取代度、不同时间羧甲基化裂褶多糖作用于H22肝癌细胞的细胞死亡率差异无统计学意义。取代度为0.67和0.93的羧甲基化裂褶多糖,对荷H22肝癌肿瘤小鼠的抑瘤率分别为41.3%和37.9%;取代度为1.14的羧甲基化裂褶多糖则未表现出抑瘤作用。结论:羧甲基化裂褶多糖在细胞水平上对H22小鼠肝癌细胞株无抑制作用;取代度为0.67和0.93的羧甲基化裂褶多糖对小鼠H22肝癌具有一定的抗癌作用,其机制并不是直接抑制癌细胞,而是通过机体因素后间接抑制肿瘤的生长,是一种具有开发潜力的新的候选抗癌药物。

美花风毛菊的抗肝癌活性研究

本研究探究美花风毛菊[Saussurea pulchella(Fisch.)Fisch]对肝癌的抑制作用。采用CCK-8法检测美花风毛菊醇提取物的乙酸乙酯萃取部位(EtOAc extract from Saussurea pulchella,ESP)对人肝癌HepG2细胞株增殖的抑制作用;继而建立H22肝癌荷瘤小鼠模型,灌胃给予ESP(100 mg/kg、200 mg/kg、400 mg/kg),连续给药14 d。以肿瘤重量、脏器指数、白细胞介素-2(IL-2)、肿瘤坏死因子-(TNF-α)、血管内皮生长因子(VEGF)、谷草转氨酶(AST)、谷丙转氨酶(ALT)、血尿素氮(BUN)、肌酐(CRE)、肿瘤和肝肾病理学检查等为评价指标,测定ESP的抗肝癌作用。结果显示,ESP具有抑制HepG2细胞株增殖的作用;ESP还可抑制H22荷瘤小鼠肿瘤的生长,增加TNF-和IL-2含量,减少VEGF含量,回调ALT、AST、BUN以及CRE含量,缓解荷瘤小鼠肝肾功能损伤。从而得出结论:美花风毛菊乙醇提取物的乙酸乙酯萃取部位具有较好的抗肝癌活性。

叶下珠复方对H_(22)肝癌小鼠的体内抑瘤作用研究

目的研究叶下珠复方对H22肝癌小鼠的体内抑瘤作用。方法建立H22细胞移植性肿瘤模型小鼠,随机分为模型对照组、阳性对照组、叶下珠复方低剂量组[0.2g/(kg·d)]、叶下珠复方中剂量组[1.0g/(kg·d)]、叶下珠复方高剂量组[5.0g/(kg·d)]共5组,连续给药8天后处死,测量小鼠的瘤重、胸腺指数、脾指数,并计算肿瘤生长抑制率。结果叶下珠复方低、中、高剂量组的抑瘤率分别为50.3%、49.9%、50.3%,与模型对照组相比,有显著性差异,但低、中、高剂量组间的肿瘤抑制率没有统计学差异。结论叶下珠复方对H22小鼠肝癌细胞有抑制作用,但肿瘤生长抑制率与给药剂量间不存在量效关系。

小半夏加茯苓汤及其组分对H22荷瘤小鼠的抑瘤作用和脾脏caspase-3基因表达的影响

目的:探讨小半夏加茯苓汤(简称XBPF)及其组分对H22荷瘤小鼠的抑瘤作用和脾脏组织caspase-3基因表达的影响。方法:通过给昆明小鼠接种H22肿瘤细胞,建立荷瘤小鼠模型,将60只小鼠分为空白对照组、模型组、多糖组、姜辣素组、XBPF组和顺铂组,干预15d后,观察抑瘤率,运用逆转录聚合酶链式反应(RT-PCR)法检测小鼠脾脏细胞中caspase-3基因的表达情况。结果:与模型组比较,XBPF组具有显著抑瘤作用(P<0.01),而且XBPF组的抑瘤作用强于多糖组和姜辣素组(P<0.05)。与模型组对比,XBPF组小鼠脾脏caspase-3基因的表达明显增多(P<0.01);XBPF组caspase-3基因的表达比多糖组和姜辣素组增多(P<0.05)。结论:XBPF对H22荷瘤小鼠肿瘤生长具有明显抑制作用,其机制可能与增强凋亡基因caspase-3表达有关。

TNP-470对小鼠肝癌H22腹水瘤的治疗研究

目的探讨TNP-470治疗小鼠肝癌H22腹水瘤的疗效及机制。方法体外采用细胞增生法和迁移法探讨TNF-470的治疗机制;体内建立H22腹水瘤小鼠模型评价TNP-470的疗效。结果TNP-470对瘤细胞H22的增生、血管内皮细胞HMEC的增生和迁移都有抑制作用;能明显提高小鼠生活质量、降低腹水的产生和瘤细胞的存活率及小鼠失明率,延长生存期。结论TNP-470对荷H22腹水瘤小鼠有明显疗效。